Ana Acuna-Villaorduna, MD
Medical Oncology · Farmington, CTNPI 1538574926
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Merck at 42.9% of the total. 2025 is the largest year on record at $143, more than ten times the $12 reported in 2020. That places this record below the midpoint for medical oncology clinicians in CT, where the typical reported total is $3,212.
Across 8 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$83
- Tersera Therapeutics LLC$38
- Springworks Therapeutics, Inc.$31
- Astellas Pharma US Inc$30
- Amgen$12
Across 30 payments — averaging $14,638 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$292K
- Takeda Pharmaceuticals U.S.A., Inc.$114K
- E.r. Squibb & Sons, L.L.C.$34K
What the payments were for
- Food & beverage$193100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $83 |
| Tersera Therapeutics LLC | 2 | $38 |
| Springworks Therapeutics, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $30 |
| Amgen | 1 | $12 |
How this compares
$193 in reported general payments places this provider in the 30th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Farmington
- Margaret CallahanFarmington$33K
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Joseph McLaughlinManchester$200K
- Francine FossNew Haven$193K
- William OhGreenwich$162K
- Anne ChiangNew Haven$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.